Business Description
Maravai LifeSciences Holdings Inc
NAICS : 541714
SIC : 2834
ISIN : US56600D1072
Share Class Description:
MEX:MRVI: Ordinary Shares - Class ATotal Employee Number:
416Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.61 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 1.28 | |||||
Debt-to-EBITDA | -2.6 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.45 | |||||
Beneish M-Score | -2 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.1 | |||||
3-Year Book Growth Rate | -29.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.24 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.95 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.91 | |||||
Quick Ratio | 4.96 | |||||
Cash Ratio | 3.89 | |||||
Days Inventory | 112.31 | |||||
Days Sales Outstanding | 49.14 | |||||
Days Payable | 20.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 14.12 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 29.29 | |||||
Operating Margin % | -44.49 | |||||
Net Margin % | -51.07 | |||||
EBITDA Margin % | -50.95 | |||||
FCF Margin % | -25.99 | |||||
OCF Margin % | -19.58 | |||||
ROE % | -42.3 | |||||
ROA % | -12.48 | |||||
ROIC % | -15.81 | |||||
3-Year ROIIC % | 60.16 | |||||
ROC (Joel Greenblatt) % | -79.92 | |||||
ROCE % | -20.84 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1808.51 | |||||
PS Ratio | 4.28 | |||||
PB Ratio | 4.21 | |||||
EV-to-EBIT | -7.08 | |||||
EV-to-Forward-EBIT | 195.9 | |||||
EV-to-EBITDA | -11.06 | |||||
EV-to-Forward-EBITDA | 38.17 | |||||
EV-to-Revenue | 5.63 | |||||
EV-to-Forward-Revenue | 6.24 | |||||
EV-to-FCF | -21.93 | |||||
Price-to-GF-Value | 1.58 | |||||
Price-to-Projected-FCF | 0.54 | |||||
Earnings Yield (Greenblatt) % | -14.12 | |||||
FCF Yield % | -5.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maravai LifeSciences Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 3,741.824 | ||
| EPS (TTM) (MXN) | -13.153 | ||
| Beta | -1.4907 | ||
| 3-Year Sharpe Ratio | -0.8 | ||
| 3-Year Sortino Ratio | -0.79 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 85 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 85 - 85 | ||
| Shares Outstanding (Mil) | 147.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maravai LifeSciences Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maravai LifeSciences Holdings Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 124 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 17:00 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 37 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 12:50 | 85.00 (+0.00%) | ||
| General meeting for 2026 | 2026-05-26 14:30 | 85.00 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:00 | 85.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 85.00 (+0.00%) | ||
| Annual report for 2025 | 2026-02-26 | 85.00 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 17:00 | 85.00 (+0.00%) |
Show
Entries
Maravai LifeSciences Holdings Inc Frequently Asked Questions
What is Maravai LifeSciences Holdings Inc(MEX:MRVI)'s stock price today?
The current price of MEX:MRVI is MXN85.00. The 52 week high of MEX:MRVI is MXN85.00 and 52 week low is MXN85.00.
When is next earnings date of Maravai LifeSciences Holdings Inc(MEX:MRVI)?
The next earnings date of Maravai LifeSciences Holdings Inc(MEX:MRVI) is 2026-08-11 Est..
Does Maravai LifeSciences Holdings Inc(MEX:MRVI) pay dividends? If so, how much?
Maravai LifeSciences Holdings Inc(MEX:MRVI) does not pay dividend.
Press Release
Articles on Maravai LifeSciences Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers